

CSL Seqirus

CSL Seqirus: A Global Leader in Flu

CSL Seqirus proudly stands on the front lines of public health as **the only global vaccine manufacturer with flu at its core**. With more than 100 years of expertise, this singular focus on influenza has allowed CSL Seqirus to advance public health through its enhanced flu vaccines that improve clinical outcomes for both children and adults.*^{1,2}

Having the largest cell-based flu manufacturing facility in the world ensures CSL Seqirus' ability to meet demand, no matter how unpredictable. Watch this [video](#) to learn more.

*Enhanced is defined as being differentiated compared to standard egg-based influenza vaccines.

Enhanced Influenza Vaccine Portfolio

CSL Seqirus is the only vaccine manufacturer with a fully enhanced influenza vaccine portfolio, backed by both randomized clinical trial data and real-world evidence, that improves clinical outcomes for all eligible persons 6+ months¹⁻⁴:

FLUCELVAX® (Influenza Vaccine) pre-filled syringe



- **Fast facts**

- The first and only enhanced flu vaccine for patients 6+ months¹
- Only FLUCELVAX has shown a real-world clinical benefit vs standard egg-based vaccines in both children and adults⁵
- The only cell-based flu vaccine to avoid mutations during production that can reduce vaccine effectiveness^{1,6-8}
- During any trimester of pregnancy, FLUCELVAX demonstrated no increased risk of major birth defects and miscarriages^{†1}
- Available through Vaccines for Children
- Recommended by ACIP and AAP^{9,10}

- **Resources**

- [Healthcare Professional Brochure](#): Instill greater confidence in clinical decision making for healthcare professionals by highlighting the benefits of FLUCELVAX
- [Patient Brochure](#): Educate caregivers and/or patients on vaccination with FLUCELVAX

- **Video:** Provide ~3-minute overview for healthcare professionals on what differentiates FLUCELVAX from other flu vaccines


†Based on a PubMed search conducted 3/17/25 for published English-language real-world evidence (RWE) studies that included relative vaccine effectiveness vs a standard flu vaccine comparator.

‡US Prospective Pregnancy Exposure Registry of women vaccinated with FLUCELVAX (quadrivalent) from 2017-2020. A total of 665 pregnancy outcomes were reported, of which 27%, 42%, and 31% of the pregnancies were exposed to FLUCELVAX during the 1st, 2nd, and 3rd trimester, respectively.

Click here for FLUCELVAX's [full Prescribing Information](#).

FLUAD® (Adjuvanted Influenza Vaccine) pre-filled syringe

FLUAD®
influenza vaccine,
adjuvanted



● Fast facts

- Preferentially recommended by ACIP for adults 65+ over standard-dose influenza vaccines⁹
- An adjuvanted flu vaccine designed to boost weakened immune systems and address strain mismatch for adults 65+¹¹⁻¹³
- Adjuvanted FLUAD strengthens, broadens, and lengthens the immune response more than antigen alone¹¹⁻¹³

● Resources

- **Healthcare Professional Brochure:** Instill greater confidence in clinical decision making for healthcare professionals by highlighting the benefits of FLUAD
- **Patient Brochure:** Educate caregivers and/or patients on vaccination with FLUAD
- **Video:** Provide ~3-minute overview for healthcare professionals on what differentiates FLUAD from other flu vaccines

Click here for FLUAD's [full Prescribing Information](#).

Operational Excellence

Season after season, CSL Seqirus extends its proven track record of supply reliability and efficiency. Over the past 4 seasons, CSL Seqirus has delivered 100% of orders on-time and in-full by mid-October—shipped 2 weeks ahead of original customer contract commitments.

Further, FLUCELVAX is the only enhanced flu vaccine that offers the operational benefit of a single SKU for all eligible individuals aged 6 months through 64 years before switching to FLUAD for all eligible persons 65 years and older.

Billing and Coding Support

CSL Seqirus offers competitive pricing and discounts for its portfolio of enhanced flu vaccines. Please see below for the FLUCELVAX and FLUAD CPT codes along with helpful coding and billing materials that provide support for the financial aspect of your flu campaigns:

- [FLUCELVAX Coding and Billing Guide](#): Helps healthcare professionals efficiently process reimbursement through accurate and convenient access to FLUCELVAX's coding and billing details
 - **CPT code: 90661**
- [FLUAD Coding and Billing Guide](#): Helps healthcare professionals efficiently process reimbursement through accurate and convenient access to FLUAD's coding and billing details
 - **CPT code: 90653**
- [Coding and Billing Webinar](#): Takes you through the current CPT, NDC, HCPCS, and ICD-10 codes to ensure you have what you need to accurately code and bill CSL Seqirus flu vaccines. For any questions, please contact reimbursement support at (855) 358-8966, option 2

Order FLUCELVAX and FLUAD today and partner with the experts in flu.

FLUAD® (Influenza Vaccine, Adjuvanted) and **FLUCELVAX®** (Influenza Vaccine)

INDICATION AND IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Do not administer FLUAD to anyone with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or to a previous influenza vaccine.

Do not administer FLUCELVAX to anyone with a history of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine.

WARNINGS AND PRECAUTIONS

If Guillain-Barré syndrome (GBS) has occurred within 6 weeks of receipt of previous influenza vaccine, the decision to give FLUAD or FLUCELVAX should be based on careful consideration of the potential benefits and risks.

Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of FLUAD or FLUCELVAX.

Syncope (fainting) may occur in association with administration of injectable vaccines. Procedures should be in place to avoid injury from fainting.

The immune response to FLUAD and FLUCELVAX in immunocompromised persons, including individuals receiving immunosuppressive therapy, may be lower than in immunocompetent individuals.

Vaccination with FLUAD or FLUCELVAX may not protect all vaccine recipients against influenza disease.

ADVERSE REACTIONS

FLUAD:

The most common ($\geq 10\%$) local and systemic adverse reactions in adults 65 years of age and older who received FLUAD were injection site pain (25%), injection site tenderness (21%), myalgia (15%), fatigue (13%) and headache (13%). Other adverse events may occur.

FLUCELVAX:

Data for FLUCELVAX QUADRIVALENT are relevant to FLUCELVAX because both vaccines are manufactured using the same process and have overlapping compositions.

In children 6 months through 3 years of age who received FLUCELVAX QUADRIVALENT, the most commonly reported injection-site adverse reactions were tenderness (28%), erythema (26%), induration (17%) and ecchymosis (11%). The most common systemic adverse reactions were irritability (28%), sleepiness (27%), diarrhea (18%) and change of eating habits (17%).

In children 4 through 8 years of age who received FLUCELVAX, the most commonly reported local injection-site adverse reactions were pain (29%) and erythema (11%). The most common systemic adverse reaction was fatigue (10%).

In children and adolescents 9 through 17 years of age who received FLUCELVAX, the most commonly reported injection-site adverse reactions were pain (34%) and erythema (14%). The most common systemic adverse reactions were myalgia (15%) and headache (14%).

In adults 18 through 64 years of age who received FLUCELVAX, the most commonly reported injection-site adverse reactions were pain (28%) and erythema (13%). The most common systemic adverse reactions were headache (16%), fatigue (12%), myalgia (11%) and malaise (10%).

In adults ≥ 65 years who received FLUCELVAX the most commonly reported injection-site reaction was erythema (10%). The most common systemic adverse reactions were fatigue (11%), headache (10%) and malaise (10%).

Other adverse events may occur.

To report SUSPECTED ADVERSE REACTIONS, contact CSL Seqirus at 1-855-358-8966 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

INDICATIONS AND USAGE

FLUAD is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUAD is approved for use in adults 65 years of age and older.

This indication is approved under accelerated approval based on the immune response elicited by FLUAD. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

FLUCELVAX is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUCELVAX is approved for use in persons 6 months of age and older.

Before administration, please see the full US Prescribing Information for [FLUAD](#) and [FLUCELVAX](#).

References: **1.** FLUCELVAX. Package insert. Seqirus Inc. **2.** FLUAD. Package insert. Seqirus Inc. **3.** Coleman BL, et al. *Influenza Other Respir Viruses*. 2021;15(6):813-823. **4.** Coleman BL, et al. *Vaccines (Basel)*. 2023;11(10):1607. **5.** Data on file. Seqirus Inc; 2025. **6.** Rockman S, et al. *Vaccines (Basel)*. 2022;11(1):52. **7.** Rajaram S, et al. *Ther Adv Vaccines Immunother*. 2020;8:2515135520908121. **8.** CDC. Cell-based flu vaccines. Accessed August 25, 2025. <https://www.cdc.gov/flu/vaccine-types/cell-based.html> **9.** Grohskopf LA, et al. *MMWR Morb Mortal Wkly Rep*. 2025;74(32):500-507. **10.** Committee on Infectious Diseases. *Pediatrics*. 2024;154(4):e2024068507. **11.** O'Hagan DT, et al. *Vaccine*. 2012;30(29):4341-4348. **12.** O'Hagan DT, et al. *Expert Rev Vaccines*. 2013;12(1):13-30. **13.** Banzhoff A, et al. *Influenza Other Respir Viruses*. 2008;2(6):243-249.

For US Healthcare Professional Use Only

flu360, FLUAD, FLUCELVAX, and FLUCELVAX QUADRIVALENT are registered trademarks of Seqirus UK Limited or its affiliates.

Seqirus USA Inc., 25 Deforest Avenue, Summit, NJ 07901, USA

©2026 Seqirus USA Inc. November 2025 USA-SEQ-26-0015